• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Conformis could face Nasdaq delisting

Conformis could face Nasdaq delisting

January 4, 2022 By Sean Whooley

ConformisConformis (NSDQ:CFMS) announced today that it is not in compliance with the minimum bid price requirement for continued Nasdaq listing.

The company received a letter from Nasdaq on Dec. 31, 2021, notifying it that the closing bid price for its common stock had been below $1 for the previous 30 consecutive business days, meaning Conformis is not in compliance with the requirement for continued inclusion on the market.

According to a news release, the notification has no immediate effect on the listing of the Billerica, Massachusetts–based company’s common stock on the Nasdaq market.

Under the Nasdaq rules, Conformis has 180 calendar days to regain compliance by having its common stock trade at $1 or higher for a minimum of 10 consecutive business days. Suppose the company does not regain compliance by June 29, 2022. In that case, it may be eligible for an additional 180 calendar days if it meets the continued listing requirement for the market value of publicly held shares and all other listing standards aside from the bid price requirement.

Conformis would need to notify Nasdaq in writing of its intention to cure the deficiency during the second compliance period. If it is not eligible or it appears to Nasdaq that Conformis can not make up the ground during the second compliance period, the company’s stock will be subject to delisting.

If Nasdaq notifies Conformis of its stock being subject to delisting, the company can appeal the determination, but there is no guarantee that Nasdaq would grant its request for continued listing.

Conformis said it will “take all reasonable measures available” to comply with Nasdaq’s listing rules.

Filed Under: Business/Financial News, Featured, Implants, News Well, Orthopedics, Wall Street Beat Tagged With: conformis, NASDAQ

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy